PROGRAMMA.ANN.MEET.2017.rev.del 13 Gen.2017 · 12.15‐12.30 External validation of the ITA.LI.CA...

A I S F ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

Riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998 Iscritta nell’Elenco di cui all'art. 1, comma 353, della Legge 23.12.2005 n. 266, D.P.C.M. 15.4.2011

Iscritta nell'Elenco di cui all'art. 14, comma 1, del D.L. 14.3.2005, n. 35, convertito nella Legge 14.5.2005 n. 80, D.P.C.M. 15.4.2011

50th AISF Annual Meeting Rome, February 23rd‐24th, 2017

S C I E N T I F I C P ROG R AMME

Thursday, February 23rd

08.30‐10.00 Selected Oral Communications (NAFLD/ALD clinical and experimental) Chairpersons: A.L. Fracanzani, Milan F. Nascimbeni, Modena

08.30‐08.45 Increased hepatic glucose production and insulin resistance are associated to increased plasma concentrations of glucogenic amino acids in subjects with NAFLD

M. Gaggini, C. Rosso, F. Carli, V. Della Latta, D. Ciociaro, M. Marietti, E. Buzzigoli, M.L. Abate, R. Gambino, M. Cassader, A. Smedile, E. Bugianesi, A. Gastaldelli ‐ Pisa, Turin

08.45‐09.00 The hepatic expression of lysosomal acid lipase (LAL) is reduced in NAFLD patients, and associated with features of genetically‐determined LAL deficiency and NAFLD activity score

U. Vespasiani‐Gentilucci, F. Valentini, S. Carotti, F. Vorini, M. Zingariello, M. Francesconi, G. Galati, P. Gallo, A. De Vincentis, C. Dell’Unto, S. Morini, A. Picardi ‐ Rome

09.00‐09.15 Serial combination of noninvasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with nonalcoholic fatty liver disease

S. Petta, V.W‐S. Wong, C. Cammà, J‐B. Hiriart, G.L‐H. Wong, J. Vergniol, A.W‐H. Chan, V. Di Marco, W. Merrouche, H.L‐Y. Chan, F. Marra, B. Le‐Bail, U. Arena, A. Craxì, V. de Ledinghen ‐ Palermo, Hong Kong, Pessac (France), Florence, Bordeaux (France)

09.15‐09.30 The combination of mucus‐degrading gram‐negative bacteria and reduced antimicrobial peptides drives adipose tissue inflammation and NAFLD progression in mice lacking NLRP3‐inflammasome

I. Pierantonelli, C. Rychlicki, D. Giordano, A. Giordano, S. Uzzau, A. Gastaldelli, L. Sartini, L. Trozzi, A. Benedetti, M. Marzioni, S. Cinti, G. Svegliati‐Baroni Ancona, Alghero (SS), Sassari, Pisa

09.30‐09.45 Steatohepatitis and type 2 diabetes mellitus are influenced by genetic susceptibility to increased intestinal permeability in patients with non‐alcoholic fatty liver disease

V. Giorgio, L. Miele, S. Petta, A. Liguori, R. Pastorino, G. Marrone, M. Biolato, C. Araneo, F.G. Vaccaro, C. Cefalo, D. Arzani, G.L. Rapaccini, A. Gasbarrini, S. Boccia, A. Craxì, A. Grieco ‐ Rome, Palermo

09.45‐10.00 Down‐regulation of hepatic MBOAT7 by hyperinsulinemia favors steatosis development

M. Meroni, P. Dongiovanni, R. Rametta, G.A. Bassani, S. Badiali, S. Romeo, S. Gatti, L. Valenti ‐ Milan, Gothenburg (Sweden)

10.00‐10.30 State‐of‐the‐Art Lecture Introduced by: A. Gasbarrini, Rome How to translate research into policy

change R. Guerra, Rome

10.30‐11.00 Coffee break and Posters view Tutors: L. Maroni, Ancona F. Salomone, Catania

11.00‐12.15 General Assembly II

12.15‐13.15 Selected Oral Communications (Hepatocellular carcinoma clinical and experimental)

Chairpersons: G. Cabibbo, Palermo F. Farinati, Padua

12.15‐12.30 External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: a multicenter cohort study

E. Dionigi, M. Borzio, A. Rossini, M. Marignani, R. Sacco, I. De Sio, E. Bertolini, G. Francica, A. Giacomin, G. Parisi, S. Vicari, A. Toldi, A. Salmi, S. Boccia, A. Maringhini, F. Fornari ‐ Melegnano (MI), Brescia, Rome, Pisa, Naples, Castelvolturno (CE), Padua, Feltre (BL), Bologna, Como, Verona, Ferrara, Palermo, Piacenza




12.30‐12.45 The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: a multicentre cohort study

A. Vitale, F. Farinati, T.L. Huo, F. Trevisani, E.G. Giannini, F. Piscaglia, U. Cillo ‐ Padua, Taipei (Taiwan), Bologna, Genoa

12.45‐13.00 Oncostatin M induces increased invasiveness and angiogenesis in hepatic cancer cells through HIF1α‐related release of VEGF‐A

B. Foglia, S. Cannito, E. Morello, C. Turato, G. Di Maira, E. Novo, S. Colombatto, P. Pontisso, F. Marra, M. Parola ‐ Turin, Padua, Florence

13.00‐13.15 Impact of natural killer (NK) cells receptors gene haplotypes on the development of hepatocarcinoma in cirrhotic patients

S. Onali, R. Littera, M. Casale, F. Capraro, C. Balestrieri, F. Figorilli, G. Serra, E. Congeddu, P. Ragatzu, R. Maddi, M. Serra, V. Loi, M. Trucas, C. Carcassi, L. Chessa Cagliari

13.15‐13.45 Young Investigator Lecture Introduced by: G. Marchesini Reggiani, Bologna Hepatitis C virus and metabolism S. Petta, Palermo

13.45‐14.45 Lunch break and Posters view Tutors: R. D’Ambrosio, Milan C. Rosso, Turin

14.45‐15.30 2015 AISF Fellowships Report Introduced by: M. Marzioni, Ancona

14.45‐15.00 Generation of an in vitro model of Primary Sclerosing Cholangitis

D. Costantini, Rome

15.00‐15.15 The Klotho‐beta (KLB) variant rs17618244 influences circulating levels of KLB and severity of disease in paediatric patients with NAFLD

A. Crudele, Rome

15.15‐15.30 Ischemia/Reperfusion damage modulation in steatotic liver through Adenosine receptors stimulation

C. Imarisio, Novara

15.30‐16.00 State‐of‐the‐Art Lecture Introduced by: E.G. Giannini, Genoa The changing epidemiology of liver diseases

in Europe M. Peck‐Radosavljevic, Klagenfurt‐Austria

16.00‐16.15 Presentation of the AISF prize for the 2 best Italian papers in 2015

Introduced by: C. Cammà, Palermo

16.15‐16.45 Coffee break and Posters view Tutors: R. D’Ambrosio, Milan C. Rosso, Turin

16.45‐18.30 Selected Oral Communications (Hepatitis C, B and delta clinical) Chairpersons: A. Aghemo, Milan U. Vespasiani‐Gentilucci, Rome

16.45‐17.00 Efficacy of oral direct acting antivirals for treatment of advanced chronic hepatitis or compensated cirrhosis due to Hepatitis C virus infection: the real‐life experience of the Sicily registry

I. Cacciola, S. Petta, M. Distefano, M.R. Cannavò, A. Davì, S. Madonia, V. Calvaruso, L. Larocca, F. Di Lorenzo, A. Digiacomo, G. Bertino, A. Licata, F. Latteri, F. Benanti, R. Volpes, L. Guarneri, A. Averna, I. Scalisi, C. Iacobello, P. Colletti, F. Cartabellotta, V. Portelli, M. Russello, G. Scifo, G. Squadrito, G. Raimondo, A. Craxì, V. Di Marco on behalf of RESIST‐HCV (Rete Sicilia Selezione Terapia ‐ HCV)

17.00‐17.15 Role of SerpinB3 in the stimulation of macrophage activation marker sCD163 in HCV infected patients

A. Martini, A. Cappon, A.Biasiolo, C. Turato, P. Pontisso ‐ Padua

17.15‐17.30 Peripheral and intrahepatic virological phenotyping in HBeAg negative Chronic Hepatitis B to evaluate risk of disease progression and HCC in the “grey‐zone” viral load cohort: can grey‐zone patients be candidate to treatment?

R. Salpini, L. Colagrossi, A. Battisti, N. Hansi, C.F. Perno, U.S. Gill, P.T.F. Kennedy, V. Svicher ‐ Rome, London (UK)

17.30‐17.45 The challenge of HCV‐retreatment after DAA‐failure: Italian real‐life from VIRONET‐C network

V. Cento, S. Barbaliscia, V.C. Di Maio, C. Masetti, C. Minichini, C.F. Magni, V. Micheli, S. Marenco, L.A. Nicolini, B. Bruzzone, Y. Troshina, C. Baiguera, C. Dentone, V. Calvaruso, S. Paolucci, M. Melis, M. Aragri, A. Bertoli, I. Lenci, S. Landonio, M. Schiavini, L. Sticchi, T. Ruggiero, E. Polilli, V. Messina, A. Pellicelli, L. Boglione, R. Cozzolongo, M. Biolato, F. Morisco, M. Siciliano, G. Parruti, G. Barbarini, A. Craxì, S. Babudieri, M. Puoti,




A. Ciancio, G. Rizzardini, N. Coppola, M. Angelico, C.F. Perno, F. Ceccherini‐Silberstein on behalf of VIRONET‐C ‐ Rome, Naples, Milan, Genoa, Turin, Sanremo (IM), Palermo, Pavia, Sassari, Pescara, Caserta, Castellana Grotte (BA), Pavia

17.45‐18.00 High rates of renal tubular damage in HBV monoinfected patients long‐term treated with Tenofovir: a cross‐sectional, single center, real‐life study in 414 patients

G. Grossi, A. Loglio, F. Facchetti, E. Galmozzi, M. Colombo, P. Lampertico ‐ Milan, Rozzano (MI)

18.00‐18.15 Prothrombotic microparticles and risk of portal vein thrombosis in patients with HCV‐related liver cirrhosis who underwent DAA antiviral therapy

A. Zanetto, E. Campello, C.M. Radu, S. Shalaby, E. Franceschet, A.M. Frigo, A. Ferrarese, I. Bortoluzzi, M. Gambato, G. Germani, M. Senzolo, A. Floreani, F. Farinati, P. Burra, P. Simioni, F.P. Russo Padua

18.15‐18.30 Abnormal microvasculature in chronic viral hepatitis

S. Sarcognato, F. Farinati, R. Cardin, F.P. Russo, M. Piciocchi, V. Guzzardo, L. Giacomelli, M. Guido ‐ Padua

Friday, February 24th 08.30‐10.00 Selected Oral Communications (Liver failure, hepatobiliary surgery, and

transplantation) Chairpersons: A. Cucchetti, Bologna R. Volpes, Palermo

08.30‐08.45 External validation of the HCC‐MELD score for patients with hepatocellular carcinoma waiting for liver transplantation

A. Vitale, A.C. Frigo, P. Burra, P. Angeli, G. Zanus, U. Cillo ‐ Padua

08.45‐09.00 Entecavir or Tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: a 5‐year follow‐up study after Hepatitis B immunoglobulin withdrawal

M.A. Manini, M. Bruce, I. Carey, G. Whitehouse, B. Wang, E. Gonsalkorala, A. Considine, P. Lampertico, K. Agarwal London (UK), Milan

09.00‐09.15 A new strategy to improve the liver engraftment efficiency of transplanted human biliary tree stem/progenitor cells (hBTSCs): cell coating with hyaluronic acid

L. Nevi, G. Carpino, D. Costantini, V. Cardinale, O. Riccioni, S. Di Matteo, F. Melandro, P.B. Berloco, L. Reid, E. Gaudio, D. Alvaro ‐ Rome, Chapel Hill (USA)

09.15‐09.30 Parenchymal sparing vs. anatomic resection for HCC: a propensity score analysis

S. Famularo, A. Giani, S. Di Sandro, M. Sandini, A. Giacomoni, E. Pinotti, L. Nespoli, L. Gianotti, L. De Carlis, F. Romano Milan, Monza (MB)

09.30‐09.45 The survival benefit of laparoscopic ablation over trans‐arterial chemoembolization in patients with hepatocellular carcinoma ineligible for liver resection or percutaneous ablation

A. Bertacco, A. Marchini, A. Vitale, C. Ungaro, F. D'Amico, E. Gringeri, D. Neri, D. Bassi, G. Zanus, R. Carandina, C. Aliberti, U. Cillo Padua

09.45‐10.00 Outcome of liver transplant recipients after the first episode of bacterial infection

A. Ferrarese, A. Zanetto, G. Germani, M. Gambato, F.P. Russo, U. Cillo, P. Angeli, P. Burra, M. Senzolo ‐ Padua

10.00‐10.30 State‐of‐the‐Art Lecture Introduced by: A. Craxì, Palermo Eradication, elimination or disease control

of HCV infection A. Alberti, Padua

10.30‐11.00 Coffee break and Posters view Tutors: L. Maroni, Ancona F. Salomone, Catania

11.00‐12.20 Symposium "A systems medicine approach to liver diseases"

Chairpersons: D. Alvaro, Rome F. Bonino, Pisa 11.00‐11.20 Large‐scale computational models of liver

metabolism: how far from the clinics? D. Rozman, Ljubljana‐Slovenia

11.20‐11.40 The role of genomics and biomarkers as a guide to diagnosis and therapeutic choices for patients with rare liver diseases

P. Invernizzi, Milan




11.40‐12.00 How the use of large clinical databases may improve the management of patients with liver cancer ‐ F. Trevisani, Bologna

12.00‐12.20 Discussion

12.20‐13.35 Selected Oral Communications (Autoimmune & biliary diseases; miscellaneous)

Chairpersons: A. Lleo De Nalda, Rozzano F. Morisco, Naples

12.20‐12.35 Identification of Twinfilin‐1 as a key regulator of cholangiocyte biological response to injury: evidence for a possible role of ageing in the progression of cholangiopathies

L. Maroni, C. Pinto, D.M. Giordano, S. Saccomanno, C. Rychlicki, L. Trozzi, M.C. Albertini, F. Orlando, E. Melum, J. Banales, A. Benedetti, G. Svegliati Baroni, M. Marzioni ‐ Ancona, Urbino, Falconara (AN), Oslo (Norway), San Sebastian (Spain)

12.35‐12.50 Metformin reduces cell migration and down‐regulates epithelial to mesenchymal transition (EMT) by AMPK / FOXO3a pathway in human intrahepatic cholangiocarcinoma (CCA)

S. Di Matteo, D. Costantini, L. Nevi, A. Lustri, C. Napoletano, J. Faccioli, F. Giulitti, E. Manzi, A.M. DeRose, M.C. Bragazzi, G. Grazi, P.B. Berloco, F. Giuliante, V. Cardinale, G. Carpino, D. Alvaro ‐ Rome

12.50‐13.05 Microgravity maintains stemness and enhance glycolytic metabolism in human hepatic and biliary tree stem/progenitor cells

D. Costantini, V. Cardinale, L. Casadei, G. Carpino, L. Nevi, S. Di Matteo, A.M. Lustri, S. Safarikia, F. Melandro, P. Berloco, C. Manetti, D. Alvaro ‐ Rome

13.05‐13.20 Epidemiology of primary biliary cholangitis in Italy: evidences from a real world database

M. Marzioni, C. Bassanelli, B. Marini, C. Ripellino, D. Urbinati, D. Alvaro ‐ Ancona, Milan, Rome

13.20‐13.35 Characterisation of the immune response in patients with drug induced liver injury

C. Bergamo, G. Germani, D. Bizzaro, C. Frasson, G. Basso, A. Ferrarese, A. Zanetto, S. Shalaby, I. Bortoluzzi, M. Gambato, M. Senzolo, F.P. Russo, P. Burra Padua

13.35‐14.35 Lunch break and Posters view Tutors: R. D’Ambrosio, Milan C. Rosso, Turin

14.35‐15.35 General Assembly III

15.35‐15.50 Presentation of the AISF distinguished service award to Prof. Alfredo Alberti

Introduced by: E.G. Giannini, Genoa

15.50‐17.20 Selected Oral Communications (Fibrosis, cirrhosis, and portal hypertension

clinical) Chairpersons: P. Angeli, Padua A. Marzano, Turin

15.50‐16.05 In‐hospital mortality and length of stay in cirrhotic patients with sepsis treated with non‐selective beta‐blockers

A. Facciorusso, R. Villani, F. Bellanti, R. Bruno, G. Fioravanti, G. Vendemiale, G. Serviddio ‐ Foggia

16.05‐16.20 Local prothrombotic state in portal venous system in cirrhosis

S. Shalaby, P. Simioni, E. Campello, S. Gavasso, A. Zanetto, F. D'Amico, E. Gringeri, U. Cillo, M. Battistel, P. Burra, M. Senzolo ‐ Padua

16.20‐16.35 In experimental ascitic cirrhosis reduction of adrenergic function by means of α2A adrenergic receptor agonists has considerable aquaretic effects

G. Sansoè, M. Aragno, R. Mastrocola, M. Ayoubi, M. Parola ‐ Turin

16.35‐16.50 Extracellular vesicles induce renal tubular cells apoptosis, oxidative stress and functional abnormalities in patients with an acute decompensation of cirrhosis

A. Brocca, D. Medica, S. Piano, A. Romano, A. Sticca, V. Cantaluppi, P. Angeli ‐ Padua, Turin, Novara

16.50‐17.05 Non‐invasive tools to ruling out large varices: RESIST‐HCV vs Baveno VI criteria in a large cohort of patients with HCV cirrhosis

V. Calvaruso, I. Cacciola, A. Licata, S. Madonia, R. Benigno, F. Bronte, S. Petta, G. Malizia, G. Bertino, M. Distefano, R. Volpes, A. Montineri, A. Digiacomo, G. Alaimo, B. Cacopardo, A. Davì, L. Guarneri, I. Scalisi, G. Mazzola, F. Cartabellotta, V. Portelli, M. Russello, G. Squadrito, G. Raimondo, A. Craxì, C. Cammà, V. Di Marco on behalf of RESIST‐HCV (Rete Sicilia Selezione Terapia‐HCV)




17.05‐17.20 Assessment of Sepsis‐3 criteria in patients with cirrhosis and bacterial infections

S. Piano, G. Chies, M. Tonon, A. Romano, E. Vettore, M. Stanco, C. Pilutti, A. Brocca, S. Fasolato, P. Angeli ‐ Padua

17.20‐17.35 Young Investigators Awards Presenters for the 2 best oral communications Basic: C. Ferrari, Parma Clinical: P. Caraceni, Bologna

Presenters for the 2 best posters Basic: L. Maroni, Ancona C. Rosso, Turin Clinical: R. D’Ambrosio, Milan F. Salomone, Catania

17.35 Closure of the Annual Meeting




Poster Session Thursday, February 23rd

N°1 Ang‐2 polymorphisms in relation to outcome in

advanced HCC patients receiving sorafenib G. Marisi, M. Scartozzi, L. Faloppi, M. Iavarone, F.G.

Foschi, G. Lauletta, M. Valgiusti, S. Cascinu, G.L. Frassineti, G. Ercolani, A. Dino, A. Casadei Gardini ‐ Meldola (FC), Cagliari, Milan, Faenza (RA), Bari, Modena, Forli

N°2 Impact of multidisciplinary team approach to liver tumors: 5‐years experience

S. Okolicsanyi, V. Pontecorvi, G. Bonato, A. Ciaccio, R. Perego, F. Romano, F. Uggeri, D. Leni, F. Vacirca, A. Gambini, A. Mariani, M. Ratti, M. Acquati, N. Zucchini, G. Bovo, R. Corso, M. Strazzabosco ‐ Milan, Monza (MB), New Haven (USA)

N°3 In experimental liver cirrhosis impaired secretion of renalase into blood may lead to organ damage and sympathetic overactivity


N°4 A novel role for heparanase in the onset of liver fibrosis

M.F. Secchi, M. Crescenzi, F.P. Russo, M. Onisto, A. Floreani ‐ Padua

N°5 Local renin‐angiotensin system in the kidney of ascitic cirrhosis: an innocent bystander or a major protagonist?


N°6 Durable response in the markers of cholestasis through 24 months of open‐label extension with obeticholic acid in italian patients with primary biliary cholangitis

P. Andreone, A. Floreani, P. Invernizzi, G. Mazzella, J. Owens‐Grillo, E. Smoot Malecha, L. MacConell Bologna, Padua, Milan, San Diego (USA), Milan

N°7 Impairment of coronary microvascular function in patients with Primary Biliary Cholangitis

N. Cazzagon, C. Dal Lin, I. Franceschet, L. Perini, G. Famoso, F. Tona, A. Floreani ‐ Padua

N°8 CEUS LI‐RADS are effective in predicting the risk hepatocellular carcinoma of liver nodules

E. Terzi, L. De Bonis, S. Leoni, F. Benevento, A. Granito, F. Tovoli, P. Pini, L. Bolondi, F. Piscaglia Bologna

N°9 Platelet count, spleen length and platelet

count/spleen length ratio for the diagnosis of oesophageal varices in patients with hepatic cirrhosis. A systematic review and meta‐analysis

A. Colli, M. Fraquelli, D. Prati, D. Conte, G. Casazza Lecco, Milan

N°10 Clinical presentation and outcomes of hepatocellular carcinoma in elderly patients referred to a tertiary center: 5‐years experience

S. Okolicsanyi, G. Bonato, V. Pontecorvi, A. Ciaccio, M. Gemma, M. Strazzabosco ‐ Milan, New Haven (USA)

N°11 Ruling‐in and ruling‐out significant fibrosis and cirrhosis using a shear wave measurement method

G. Ferraioli, L. Maiocchi, R. Lissandrin, C. Tinelli, A. De Silvestri, C. Filice ‐ Pavia

N°12 Liver stiffness fibrosis thresholds of Fibroscan cannot be adopted by all new elastography machines: a comparative study

V. Salvatore, L. Mulazzani, V. Cantisani, A. Colecchia, R. Di Donato, C. Felicani, A. Ferrarini, N. Gamal, V. Grasso, G. Marasco, E. Mazzotta, F. Ravaioli, G. Ruggieri, I. Serio, J.F. Sitouok Nkamgho, C. Serra, D. Festi, C. Schiavone, L. Bolondi, F. Piscaglia ‐ Bologna, Rome, Chieti

N°13 Autoimmune hepatitis in children and adults: a single centre experience

L. Perini, E. Nicoletto, E. Salami, P. Gaio, C. Mangini, N. Cazzagon, V. Baldo, M. Cananzi, A. Floreani Padua

N°14 Effectiveness of HCV antiviral treatment in patients with cirrhosis or advanced fibrosis and end‐stage kidney disease on dialysis

F.R. Ponziani, M. Siciliano, R. Lionetti, C. Pasquazzi, L. Gianserra, L. Lambiase, G. D’Offizi, A. Gasbarrini, M. Pompili ‐ Rome

N°15 Validation of the Bolondi stratification for intermediate stage hepatocellular carcinoma (HCC). Clinical and therapeutical implications

A. Mega, M. De Giorgio, H. Zoller, A. Finkenstedt, M. Felder, S. Fagiuoli, M. Haefner ‐ Bozen, Bergamo, Innsbruck (Austria)




N°16 Impact of direct‐acting anti‐HCV treatments before liver transplant on virological and clinical outcomes of HCV patients at one year after surgery

S. Martini, M. Sacco, S. Strona, A. Ottobrelli, F. Tandoi, S. Mirabella, D. Cocchis, M. Salizzoni, G.M. Saracco, R. Romagnoli ‐ Turin

N°17 Worsening of serum lipid profile after direct acting antiviral treatment

S. Gitto, A.F.P. Cicero, E. Loggi, M. Giovannini, F. Conti, E. Grandini, V. Guarneri, A. Scuteri, G. Vitale, C. Cursaro, C. Borghi, P. Andreone ‐ Bologna

N°18 The immunomodulatory activity of SerpinB3 an protease‐inhibitor in vivo and in vitro

A. Cappon, G. Villano, S. Quarta, A. Biasiolo, C. Turato, M. Ruvoletto, S. Sutti, S. Bruzzi, E. Novo, E. Morello, S. Cannito, E. Albano, M. Parola, P. Pontisso ‐ Padua, Novara, Turin

N°19 Hypoxia‐inducible factor 2α drives the progression of experimental non‐alcoholic fatty liver disease by stimulating hepatocyte production of histidine rich glycoprotein

S. Sutti, E. Morello, S. Cannito, E. Novo, C. Bocca, B. Foglia, S. Bruzzì, E. Bugianesi, E. Albano, M. Parola Turin, Novara

N°20 TERT promoter and CTNNB1 gene mutations represent cancer signatures specific for hepatitis B and hepatitis C related hepatocellular carcinoma

F. Pezzuto, F. Izzo, L. Buonaguro, C. Annunziata, F. Tatangelo, G. Botti, F.M. Buonaguro, M.L. Tornesello ‐ Naples

N°21 Minimal increases of alpha‐fetoprotein strongly predict HCC development in caucasian compensated HBV cirrhotics treated by entecavir or tenofovir: a 7‐year longitudinal cohort study in 225 patients

A. Loglio, G. Grossi, M. Iavarone, M. Viganò, A. Sangiovanni, M. Colombo, P. Lampertico ‐ Milan, Rozzano (MI)

N°22 MiR‐122 targets SerpinB3 and is involved in Sorafenib resistance in hepatocellular carcinoma

D. Pollutri, F. Fornari, C. Turato, G. Villano, S. Quarta, M. Ruvoletto, L. Bolondi, L. Gramantieri, P. Pontisso ‐ Bologna, Padua

N°23 Genetic variations in PD‐1 and STAT4 genes do not predict off‐treatment functional cure in IFN treated genotype D, HBeAg‐negative patients with chronic hepatitis B

E. Galmozzi, F. Facchetti, G. Grossi, A. Loglio, P. Lampertico ‐ Milan

N°24 Validation of the Baveno VI criteria for screening of esophageal varices in patients with metabolic and alcohol related compensated advanced chronic liver disease

N. Mezzina, M. Viganò, T. Giulia, S. Labanca, R. Lombardi, V.L. Mainardi, A.L. Fracanzani, P. Lampertico, M. Rumi, M. Primignani ‐ Milan

N°25 Inherited prothrombotic risk factors in children with extrahepatic portal vein obstruction (EHPVO). A case‐control study

M. Primignani, I. Martinelli, G. Tosetti, M. Cheli, P. Bucciarelli, M. Colusso, D. Alberti ‐ Milan, Bergamo, Brescia

N°26 Increase in transporter MATE‐1 expression induced by obeticholic acid correlates with higher biliary excretion of asymmetric dimethylarginine during hepatic ischemia/reperfusion injury

L.G. Di Pasqua, C. Berardo, V. Siciliano, R. Viscusi, V. Rizzo, L. Adorini, P. Richelmi, A. Ferrigno, M. Vairetti Pavia, San Diego (USA)

N°27 Clinical effectiveness of enhanced surveillance in "super‐high risk" cirrhotics as evaluated in the ITA.LI.CA database

M. D'Elia, G. Peserico, F. Pelizzaro, A. Meneghetti, A. Imondi, E. Giannini, F. Trevisani, F. Farinati Padua, Genoa, Bologna

N°28 Lobe‐specific oxidative stress and matrix metalloproteinase activation in two animal models of non‐alcoholic fatty liver disease (NAFLD)

V. Siciliano, L.G. Di Pasqua, C. Berardo, V. Rizzo, P. Richelmi, S. Perlini, A. Ferrigno, G. Palladini, M. Vairetti ‐ Pavia

N°29 Vitamin D deficiency is an independent risk factor and is predictor of infections in patients affected by HCV‐related liver cirrhosis

A.R. Buonomo, E. Zappulo, R. Scotto, B. Pinchera, A.E. Maraolo, F. Borrelli, G. Di Filippo, G. Borgia, I. Gentile ‐ Naples

N°30 Direct acting antiviral (DAA) therapy of HCV, effects on the cryoglobulinemic vasculitis: a multi center open label study

E. Mauro, L. Quartuccio, M. Ghersetti, M. Lenzi, S. Gitto, P. Andreone, P. Casarin, S. De Vita, G. Pozzato, C. Mazzaro ‐ Pordenone, Udine, Bologna, Trieste, Aviano (PN)

N°31 Dynamic risk prediction in Primary Biliary Cholangitis using the UK‐PBC cohort

M. Carbone, A. Nardi, H.F. Ainsworth, M.A. Heneghan, G.M. Hirschfield, D. Thorburn, A. Bathgate, M. Aldersley, J.M. Neuberger, D.D. Stocken, H.J. Cordell, G.J. Alexander, R.N. Sandford, D.E.J. Jones, G.F. Mells ‐ Cambridge (UK), Milan




N°32 Established cirrhosis at the time of diagnosis predicts adverse outcome in autoimmune hepatitis: a retrospective cohort study

A. Gerussi, N. Halliday, D. Roccarina, F. Saffioti, P. Polly, M. Pinzani, A. Marshall, D. Thorburn ‐ London (UK), Udine, Messina

N°33 Cirrhosis regression does not prevent hepatocellular carcinoma in patients with a sustained virological response to IFN

R. D'Ambrosio, A. Aghemo, E. Degasperi, A. Sangiovanni, M.G. Rumi, M. Fraquelli, R. Perbellini, P. Bedossa, M. Colombo, P. Lampertico ‐ Milan, Clichy (France), Rozzano (MI)

N°34 Impact of von Willebrand factor and ADAMTS‐13 on the pro‐coagulant imbalance of patients with cirrhosis

V. La Mura, A. Tripodi, N. Bitto, G. Tosetti, V. Chantarangkul, L. Baronciani, C. Valsecchi, F. Peyvandi, F. Salerno, P. Lampertico, M. Colombo, M. Primignani ‐ Milan

N°35 DAA‐based regimens in HBsAg/anti‐HCV positive patients: the need to control HBV replication to avoid HBV reactivation

M. Macera, M. Stanzione, V. Messina, G. D’Adamo, V. Sangiovanni, L. Fontanella, S. De Pascalis, G. Stornaiuolo, G. Piai, G.B. Gaeta, I. Gentile, N. Coppola ‐ Naples, Caserta, Nocera (SA)

N°36 Liver microRNA hsa‐miR‐125a‐5p may exert an oncosuppressor effect on HCC

L. Onorato, N. Coppola, G. de Stefano, M. Panella, V. Iodice, C. Minichini, N. Mosca, L. Desiato, N. Farella, M. Starace, G. Liorre, N. Potenza, E. Sagnelli, A. Russo ‐ Naples, Caserta

N°37 Prognostic role of vascular endothelial growth factor and hypoxia inducible factor in HCC patients after conventional and deb‐mediated chemoembolization

A. Meneghetti, G. Peserico, F. Pelizzaro, C. Pozzan, V. Iurilli, R. Vezzaro, R. Cardin, M. Piciocchi, D. Paccagnella, F. Farinati ‐ Padua

N°38 Absolute quantification of intrahepatic HBV covalently‐closed‐circular DNA by droplet digital PCR

G.P. Caviglia, M.L. Abate, A. Olivero, C. Rosso, A. Ciancio, E. Bugianesi, G.M. Saracco, A. Smedile Turin

N°39 Hepatocellular carcinoma and metabolic risk factors in a main reference center in Italy

R.I. Kamal Jouness, C. Rosso, M. Marietti, G.P. Caviglia, A. Nascè, D. Campion, A. Cantamessa, P. Carucci, E. Bugianesi ‐ Turin

N°40 Entecavir monotherapy improves renal function in patients developing renal side effects during long‐term Tenofovir treatment without compromising virological response: a multicenter real‐life study in 103 patients

M. Viganò, G. Grossi, A. Loglio, M. Cappelletti, S. Zaltron, F. Castelli, P. Andreone, V. Messina, R. Ganga, N. Coppola, A. Marrone, M. Russello, A. Marzano, G. Taliani, M. Fasano, S. Fagiuoli, E. Villa, F. Bronte, T. Santantonio, G. Brancaccio, F. Facchetti, P. Lampertico ‐ Milan, Brescia, Bologna, Caserta, Cagliari, Naples, Catania, Turin, Rome, Triggiano (BA), Bergamo, Modena, Palermo, Foggia

N°41 Copper levels contribute together with the myc oncogene to liver transformation

C. Porcu, L. Antonucci, B. Barbaro, C. Balsano Rome

N°42 Screening of oesophagogastric varices in virus‐related compensated advanced chronic liver disease: beyond the Baveno VI criteria

G. Tosetti, V. La Mura, A. Aghemo, P. Lampertico, R. D’Ambrosio, M. Viganò, G. Grossi, M. Fraquelli, M. Colombo, M. Primignani ‐ Milan

N°43 Clinical outcomes with long‐term Sorafenib treatment: a multicenter, real‐life study

R. Sacco, S. Parodi, T. Zolfino, C. Saitta, L. Marzi, N. Simonetti, S. Attardo, M. Rossa, G. Bresci, G. Cabibbo ‐ Pisa, Cagliari, Messina, Modena, Palermo

N°44 DAAs treatment in HCV recurrence after Liver Transplantation: clinical usefulness of non‐invasive methods

F. Ravaioli, M.R. Tamè, G. Marasco, L. Vizioli, M.C. Morelli, A.D. Pinna, F. Conti, P. Andreone, A. Colecchia, D. Festi and Research Center for the Study of Hepatitis (CRS) ‐ Bologna

N°45 Liver Stiffness and serum fibrosis biomarker variations after DAAs treatment: predictive role in HCC development in in cirrhotic patients

F. Ravaioli, G. Mazzella, P. Andreone, F. Conti, S. Brillanti, F. Buonfiglioli, I. Serio, G. Verucchi, M.L. Bacchi Reggiani, G. Marasco, A. Colecchia, D. Festi and Research Center for the Study of Hepatitis (CRS) Bologna

N°46 An elevated degree of genetic variability characterizes Hepatitis Delta Antigen (HDAg) and correlates with high levels of serum HDV‐RNA: implication for disease progression and design of new pharmacological targets

L. Colagrossi, R. Salpini, R. Scutari, A. Battisti, L. Piermatteo, A. Bertoli, C. Minichini, P. Trimoulet, H. Fleury, E. Nebuloso, M. De Cristofaro, G. Cappiello, A. Spanò, V. Malagnino, T. Mari, A. Barlattani, N. Iapadre, M. Lichtner, C.M. Mastroianni, I. Lenci, C. Pasquazzi, G.M. De Sanctis, A. Galeota Lanza, M.




Stanzione, G. Stornaiuolo, M. Marignani, L. Sarmati, M. Andreoni, M. Angelico, C.F. Perno, N. Coppola, V. Svicher ‐ Rome, Naples, Bordeaux (France), L’Aquila

N°47 Spleen stiffness measurement: a useful prognostic tool in HCV patients treated with DAAs regimens

F. Ravaioli, G. Marasco, M.L. Bacchi Reggiani, G. Mazzella, F. Buonfiglioli, A. Porro, S. Brillanti, A. Colecchia, D. Festi and Research Center for the Study of Hepatitis (CRS) ‐ Bologna

N°48 The role of Spleen Stiffness measurement as predictor of HCC recurrence after curative resection in cirrhotic patients

G. Marasco, A. Colecchia, A. Colli, G. Casazza, F. Ravaioli, A. Cucchetti, M. Cescon, A.D. Pinna, D. Festi ‐ Bologna, Lecco, Milan

N°49 Impact of adrenal dysfunction on psoas muscle thickness assessed by computed tomography in patients with liver cirrhosis

G. Privitera, L. Spadaro, D. Russo, S. Marchisello, F. Purrello ‐ Catania

N°50 Validation of a simple scoring system to predict Sorafenib effectiveness in patients with hepatocellular carcinoma

R. Tortora, A. Casadei Gardini, G. Cordone, G. Marisi, F.G. Foschi, M. Scartozzi, R. Granata, L. Faloppi, S. Cascinu, N. Silvestris, O. Brunetti, V.O. Palmieri, G. Ercoloani, G.G. Di Costanzo ‐ Naples, Meldola (FC), Faenza (RA), Cagliari, Modena, Bari, Forlì

Poster Session Friday, February 24th

N°1 Advanced BCLC hepatocellular carcinoma includes a very heterogeneous patient population treatable with different therapies and with different prognosis

F. Garuti, E.G. Giannini, L. Bucci, M. Valente, B. Lenzi, F. Trevisani on behalf of Italian Liver Cancer (ITA.LI.CA) group ‐ Bologna, Genova

N°2 A genic and epigenetic combination therapy for liver cancer

L. Rinaldi, G. Franci, V. Folliero, L. Palomba, R. Isticato, C. Zannella, R. di Francia, I. De Sio, G. Morelli, S. Lastoria, L. Altucci, C. Pedone, A. Ascione, L.E. Adinolfi, M. Galdiero ‐ Naples

N°3 Risk factors of early emergent hospital readmission and 6‐month mortality in patients with cirrhosis after a recovery from bacterial or fungal infection

F. Morando, S. Piano, S. Rosi, M. Stanco, C. Pilutti, E. Vettore, A. Romano, S. Fasolato, M. Tonon, A. Brocca, A. Sticca, P. Angeli ‐ Padua

N°4 Effectiveness of Percutaneous Ethanol Injection in relation to hepatocellular carcinoma size: a single centre experience

G.G. Di Costanzo, R. Granata, M. Sanduzzi‐Zamparelli, L. Falco, G. Cordone, R. Tortora ‐ Naples

N°5 In HBeAg‐negative chronic HBV infection, HBsAg levels profoundly differ among HBV‐genotypes and can be affected by the extent of HBsAg variability: can quantitative HBsAg truly reflect intra‐hepatic HBV reservoir?

R. Salpini, A. Battisti, O. Anastasiou, U. Gill, L. Colagrossi, A. Bertoli, L. Fabeni, V. Fini, L.

Piermatteo, A. Iuvara, V. Malagnino, C. Cerva, M. Lichtner, C. Mastroianni, G. De Sanctis, M. Paoloni, M. Marignani, C. Pasquazzi, N. Iapadre, T. Mari, G. Parruti, I. Vecchiet, L. Sarmati, M. Andreoni, M. Angelico, S. Grelli, P. Kennedy, J. Verheyen, C.F. Perno, V. Svicher ‐ Rome, Essen (Germany), London (UK), Avezzano (AQ), L’Aquila, Pescara, Chieti

N°6 Hepatocellular carcinoma recurrence rate in HCV infected patients treated with direct antiviral agents. A single center experience

R. Granata, G.G. Di Costanzo, M. Sanduzzi Zamparelli, M. Guarino, G. Cordone, G. D’Adamo, R. Tortora ‐ Naples

N°7 Effects of treatment with Maraviroc a CCR5 inhibitor on a human hepatic stellate cell line

N. Coppola, A. Perna, A. Lucariello, S. Martini, M. Macera, M.A. Carleo, G. Guerra, V. Esposito, A. De Luca ‐ Naples

N°8 Child‐Pugh score predicts ribavirin overexposure in cirrhotic patients treated with direct‐acting antiviral agents

V. Guardigni, L. Badia, M. Rinaldi, S. Ianniruberto, P. Viale, G. Verucchi ‐ Bologna

N°9 Serum markers for early diagnosis of HCC in HCV cirrhotic patients with SVR to DAA treatment

A. Sangiovanni, R. D'Ambrosio, G. Lunghi, M. Bruccoleri, E. Alimenti, M. Borghi, R. Perbellini, A. Aghemo, M. Iavarone, M. Colombo, P. Lampertico Milan, Rozzano (MI)




N°10 Eradication of HCV in patients awaiting liver transplantation does not increase drop‐out due to HCC progression

S. Shalaby, A. Zanetto, A. Vitale, A. Ferrarese, I. Bortoluzzi, M. Gambato, M. Senzolo, G. Germani, C. Mescoli, A. Romano, E. Gringeri, G. Zanus, P. Angeli, U. Cillo, P. Burra, F.P. Russo ‐ Padua

N°11 FAK depletion/inhibition reduces the expression of liver cancer stem cells markers

I. Romito, D. Gnani, S. Artuso, C. De Stefanis, N. Panera, A. Crudele, C. Balsano, E. Carcarino, V. Nobili, R. Rota, C. Leonetti, A. Alisi ‐ Rome

N°12 In HCV infected patients with cirrhosis Squamous Cell Carcinoma Antigen (SCCA)‐IgM levels may contribute to identify the individual risk of HCC development after antiviral therapy

G. Ricco, D. Cavallone, P. Pontisso, G. Fassina, A. Gallotta, P. Colombatto, F. Oliveri, V. Romagnoli, B. Coco, A. Salvati, F. Bonino, M.R. Brunetto ‐ Pisa, Padua, Venice, Chianciano Terme (SI)

N°13 Validation of Liver Imaging Reporting and Data System (LI‐RADS) Version 2014

A. Pecorelli, R. Nani, F. Sala, D. Pinelli, M. De Giorgio, G. Magini, M. Colledan, S. Fagiuoli, S. Sironi Milan, Bergamo

N°14 Multiclass HCV resistance to interferon‐free direct acting antivirals regimens in real life failures advocates for tailored second‐line therapies

V.C. Di Maio, V. Cento, I. Lenci, M. Aragri, S. Barbaliscia, S. Francioso, S. Paolucci, M. Melis, G. Verucchi, C. Masetti, N. Coppola, C.F. Magni, V. Micheli, T. Pollicino, T. Ruggiero, S. Landonio, A. Mancon, M. Starace, F. De Leonardis, F. Santopaolo, A. Bertoli, F.P. Antonucci, C. D’Ambrosio, V. Calvaruso, M.C. Sorbo, F. Morisco, C. Pasquazzi, I. Maida, A. Picciotto, A. Di Biagio, B. Bruzzone, L. Sticchi, V. Ghisetti, R. Cozzolongo, D. Romagnoli, V. Boccaccio, A. Grieco, J. Vecchiet, G. D’Ettorre, M. Merli, G.B. Gaeta, A. Ciancio, L. Marinaro, E. Polilli, P. Cacciatore, P. Andreone, G. Barbarini, R. Gulminetti, S. Novati, V. Pace Palitti, P. Tarquini, M. Puoti, V. Sangiovanni, G. De Stefano, A. Giorgini, M. Paoloni, N. Caporaso, S. Babudieri, G. Gubertini, S. Bruno, M. Andreoni, A. Pellicelli, G. Parruti, G. Raimondo, F. Baldanti, G. Rizzardini, A. Craxì, M. Angelico, C.F. Perno, F. Ceccherini‐Silberstein on behalf of HCV Virology Italian Resistance Network Group (Vironet C) ‐ Rome, Pavia, Sassari, Bologna, Naples, Milan, Messina, Turin, Palermo, Genoa, Castellana Grotte (BA), Modena, Rozzano (MI), Chieti, Pescara, Teramo, Avezzano (AQ)

N°15 Liver stiffness and portal hypertension predict failure to DAA treatment in a real‐life cohort of HCV‐infected patients treated with recommended regimens

C. Masetti, F. De Leonardis, P. Rossi, A. Bosa, D. Di Paolo, M. Milana, F. Santopaolo, A. Pecchioli, S. Di Nardi, S. Francioso, I. Lenci, L. Baiocchi, A. Brega, T. Marianelli, F. Antenucci, M. Angelico ‐ Rome

N°16 Laparoscopic ablation for HCC: proposal of a 6‐months mortality score for patient selection based on more than 1000 procedures

A. Bertacco, A. Marchini, A. Vitale, C. Ungaro, F. D'Amico, E. Gringeri, D. Neri, D. Bassi, G. Zanus, R. Carandina, C. Aliberti, U. Cillo ‐ Padua

N°17 Treatment with direct‐acting antiviral agents is associated with improvement of renal function in a cohort of HCV‐infected patients with chronic kidney disease

C. Masetti, F. De Leonardis, P. Rossi, A. Bosa, D. Di Paolo, M. Milana, F. Santopaolo, A. Pecchioli, S. Di Nardi, S. Francioso, I. Lenci, L. Baiocchi, A. Brega, F. Antenucci, T. Marianelli, M. Angelico ‐ Rome

N°18 Natural HCV resistance is common in Italy and differently associated to genotypes

M.C. Sorbo, V. Cento, A. Bertoli, I. Lenci, E. Polilli, C. Masetti, L. Gianserra, E. Teti, E. Biliotti, C.F. Magni, M. Aragri, V. Micheli, M. Melis, L.A. Nicolini, S. Marenco, V. Calvaruso, S. Paolucci, F Baldanti, F. Morisco, M. Siciliano, V. Pace Palitti, P. Andreone, B.Bruzzone, N. Coppola, T. Ruggiero, M. Lichtner, B. Menzaghi, D. Romagnoli, N. Iapadre, V.C. Di Maio, F. De Leonardis, M. Milana, P. Cacciatore, A Pieri, L. Sarmati, S. Landonio, A. Gasbarrini, M. Puoti, A. Craxì, V. Vullo, A. Pellicelli, S. Babudieri, G. Rizzardini, G. Taliani, M. Andreoni, C. Pasquazzi, G. Parruti, M. Angelico, C.F. Perno, F. Ceccherini‐Silberstein ‐ Rome, Pescara, Milan, Sassari, Genoa, Palermo, Pavia, Naples, Pescara, Bologna, Latina, Varese, Baggiovara (MO), L'Aquila, Turin

N°19 HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real‐life

V. Cento, S. Barbaliscia, I. Lenci, T. Ruggiero, C. Masetti, C.F. Magni, V. Micheli, S. Paolucci, Y. Troshina, E. Biliotti, M. Milana, M. Melis, E. Teti, L. Lambiase, B. Menzaghi, L.A. Nicolini, S. Marenco, V.C. Di Maio, M. Aragri, A. Pecchioli, A. Bertoli, F.P. Antonucci, L. Sarmati, C. Sarrecchia, M. Macera, N. Coppola, E. Danieli, D. Romagnoli, A. Pellicelli, S. Bonora, S. Babudieri, A. Di Biagio, A. Picciotto, S. Novati, M. Siciliano, V. Messina, E. Claar, F. Baldanti, C. Pasquazzi, A. Ciancio, M. Puoti, V. Ghisetti, M. Andreoni, G. Taliani, G. Rizzardini, M. Angelico, C.F. Perno, F. Ceccherini‐Silberstein




Rome, Turin, Milan, Pavia, Sassari, Varese, Genoa, Naples, Baggiovara (MO), Caserta

N°20 Impact of Acute‐on‐Chronic Liver Failure (ACLF) on response to treatment with terlipressin and albumin in patients with type 1 hepatorenal syndrome

S. Piano, H. Schmidt, X. Ariza, A. Amoros, A. Romano, E. Solà, A. Gerbes, M. Bernardi, C. Alessandria, J. Trebicka, T. Gustot, F. Nevens, V. Arroyo, P. Gines, P. Angeli ‐ Padua, Münster (Germany), Barcelona (Spain), Munich (Germany), Bologna, Turin, Bonn (Germany), Brussels (Belgium), Leuven (Belgium)

N°21 Low viremic HBeAg negative HBsAg carriers: clinical outcome and non invasive diagnostic accuracy for chronic hepatitis B or inactive infection by combinations of HBV markers

F. Oliveri, L. Surace, D. Cavallone, P. Colombatto, G. Ricco, N. Salvati, B. Coco, V. Romagnoli, R. Gattai, A. Salvati, F. Moriconi, Q. Yuan, F. Bonino, M.R. Brunetto ‐ Pisa, Xiamen (China), Chianciano Terme (SI)

N°22 Thromboelastographic evaluation of hemostatic balance in cirrhotic patients with infection

E. Nadal, P. Simioni, L. Spiezia, P. Angeli, S. Fasolato, A. Zanetto, A. Ferrarese, S. Shalaby, G. Germani, F.P. Russo, P. Burra, M. Senzolo ‐ Padua

N°23 Ultrasound‐guided Percutaneous Irreversible Electroporation (IRE) of Hepatocellular Carcinoma (HCC) not suitable for surgery or thermal ablation: initial report on safety and efficacy from a western center

A. Giorgio, P. Gatti, C. Coppola, A. Calvanese, F. Amendola, B. Santoro, M.G. Merola, F. Merola, P. Matteucci, V. Giorgio ‐ Salerno, Rome

N°24 Transjugular intrahepatic portosystemic shunt is a safe and effective approach in cirrhotic patients with splanchnic vein thrombosis

A. Airoldi, S. De Nicola, G. Perricone, M. Vangeli, R. Viganò, R. Vercelli, C. Migliorisi, M. Solcia, F. Barbosa, F. Musca, A. De Gasperi, L.S. Belli, A.G. Rampoldi ‐ Milan

N°25 Decreased alpha‐fetoprotein levels in HCV cirrhotic patients after direct‐acting antiviral agents therapy. Does this indicate a reduced risk of hepatocellular carcinoma?

F. De Leonardis, C. Masetti, P. Rossi, D. Di Paolo, A. Bosa, M. Milana, F. Santopaolo, S. Cucchiarelli, A. Pecchioli, S. Francioso, I. Lenci, A. Brega, T. Marianelli, F. Antenucci, S. Di Nardi, L. Baiocchi, M. Angelico ‐ Rome

N°26 Bacterial infection is an uncommon occurrence in cirrhotic patients undergoing endoscopic variceal ligation

S. Maimone, G. Caccamo, R. Filomia, S. Sabatini, M.S. Franzè, C. Saitta, K. Sitajolo, M.A. Aragona, F. Saffioti, C. Pitrone, I. Cacciola, G. Squadrito, G. Raimondo ‐ Messina

N°27 Frailty index is a strong predictor of in‐hospital outcomes and mortality after discharge in cirrhotic patients

G. Caccamo, G. Basile, S. Maimone, D. Vadalà, T. Crea, M.S. Franzè, A. Sitibondo, R. Filomia, C. Saitta, I. Cacciola, G. Squadrito, G. Raimondo ‐ Messina

N°28 Efficacy of early empiric antibiotic treatment and its impact on short‐term mortality in cirrhotic patients with subsequent identification of the infecting bacteria

G. Caccamo, M.S. Franzè, R. Filomia, P. Mondello, I.A. Paolucci, K. Sitajolo, M.A. Aragona, T. Lembo, C. Saitta, I. Cacciola, G. Squadrito, G. Raimondo, S. Maimone ‐ Messina

N°29 Liver Stiffness Based Model (LSPS) predicts portal hypertension (PH), esofageal varices (EV) and HCC in caucasian patients with HBV‐related cirrhisis responsive to antiviral therapy

A. Tucci , W. Debernardi Venon, C. Chialà, M. Fadda, G.M. Saracco, A. Marzano ‐ Turin

N°30 HBV reactivation in pOBI is influenced by detectable viremia at baseline rather than duration of prophylaxis with lamivudine

F. Cavallo, P. Ghione, M. Battaglini, B. Botto, D. Caracciolo, S. Ferrero, R. Passera, U. Vitolo, M. Boccadoro, A. Marzano ‐ Turin

N°31 Risk of Hepatocellular Carcinoma (HCC) Recurrence in HCV Cirrhotic Patients treated with Direct Acting Antivirals (DAAs)

G. Cabibbo, I. Cacciola, M.R. Cannavò, S. Madonia, V. Calvaruso, S. Petta, M. Distefano, L. Larocca, T. Prestileo, F. Tinè, A. Digiacomo, G. Bertino, L. Giannitrapani, F. Benanti, A. Davì, R. Volpes, I. Scalisi, C. Iacobello, G. Mazzola, F. Cartabellotta, L. Guarneri, V. Portelli, A. Averna, M. Russello, G. Scifo, G. Squadrito, G. Raimondo, A. Craxì , V. Di Marco, C. Cammà on behalf of RESIST‐HCV (Rete Sicilia Selezione Terapia ‐ HCV)

N°32 Early occurrence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct‐acting antivirals (DAAs)

V. Calvaruso, G. Cabibbo, I. Cacciola, S. Petta, S. Madonia, A. Bellia, F. Tinè, M. Distefano, L. Giannitrapani, T. Prestileo, G. Mazzola, A. Davì, L. Larocca, A. Ardiri, A. Digiacomo, M. Gussio, L. Guarneri, A. Magro, A. Averna, C. Iacobello, I. Scalisi, F. Cartabellotta, F. Savalli, M. Russello,




G. Scifo, G. Squadrito, C. Cammà, G. Raimondo, A. Craxì, V. Di Marco on behalf and RESIST‐HCV (Rete Sicilia Selezione Terapia ‐ HCV)

N°33 HLA‐G is highly expressed by plasma cells infiltrating hepatic tissue of patients affected by autoimmune hepatitis

S. Onali, F. Figorilli, E. Sanna, C. Balestrieri, G. Serra, M. Conti, F. Alba, M. Trucas, D. Fanni, G. Senes, A. Mereu, G. Faa, C. Carcassi, R. Littera, L. Chessa Cagliari

N°34 Survival and Recurrences after curative treatments of HCV‐related early Hepatocellular Carcinoma. A meta‐analysis of single arm studies

G. Cabibbo, S. Petta, M. Barbàra, G. Missale, R. Virdone, E. Caturelli, F. Piscaglia, F. Morisco, A. Colecchia, F. Farinati, E. Giannini, F. Trevisani, A. Craxì, M. Colombo, C. Cammà on behalf of the ITA.LI.CA study group ‐ Palermo, Parma, Viterbo, Bologna, Naples, Padua, Genoa, Milan

N°35 Are detectable sofosbuvir trough concentrations predictive of virological failure during anti‐HCV treatment? Preliminary evidences from the KINETI‐C study

A. De Nicolò, L. Boglione, C. Carcieri, J. Cusato, S. Mornese Pinna, F. Favata, A. Ariaudo, G. Di Perri, A. D’Avolio ‐ Turin

N°36 Prevalence and characteristics of resistance associated substitutions in DAA‐naive and DAA‐failed HCV‐3 patients in Italy

V.C. Di Maio, S. Barbaliscia, I. Lenci, E. Teti, F.P. Antonucci, V. Cento, M. Aragri, S. Paolucci, B. Bruzzone, N. Coppola, T. Ruggiero, T. Pollicino, E. Polilli, C. Pasquazzi, V. Pace Palitti, C.F. Magni, V. Micheli, A. Di Biagio, L. Sticchi, M. Melis, S. Francioso, C. Masetti, L. Foroghi, C. Sarrecchia, L. Baiocchi, S. Landonio, A. Bertoli, V. Calvaruso, F. Morisco, I. Maida, S. Marenco, A. Leo, V. Ghisetti, A. Ciancio, P. Sacchi, S. Novati, G. Brancaccio, A. Pieri, M. Puoti, P. Toniutto, V. Vullo, A. Aghemo, G. Di Perri, S. Babudieri, G. Rizzardini, S. Bruno, A. Pellicelli, G. Taliani, G. Raimondo, F. Baldanti, G.B. Gaeta, A. Craxì, G. Parruti, M. Andreoni, M. Angelico, C.F. Perno, F. Ceccherini‐Silberstein on behalf of HCV Virology Italian Resistance Network Group (Vironet C) ‐ Rome, Pavia, Genoa, Naples, Turin, Messina, Pescara, Milan, Sassari, Palermo, Rozzano (MI), Udine

N°37 Evaluation of mild cognitive dysfunction by montreal cognitive assessment test in patients with chronic HCV infection treated with direct antiviral agents

S. Onali, D.G. Pacini, C. Balestrieri, F. Figorilli, G. Serra, L. Chessa ‐ Cagliari

N°38 Comparative antiviral efficacy with higher ALT normalization of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in HBeAg‐negative, Genotype D Chronic Hepatitis B

G. Ricco, M. Buti, M. Omata, Y.J. Kim, B. Coco, D. Samuel, J.F. Flaherty, L. Lin, A. Gaggar, E. Ceausu, U.S. Akarca, M.J. Tong, H.L. Chan, M.R. Brunetto ‐ Pisa, Barcelona (Spain), Kōfu‐shi (Japan), Seoul (Korea), Villejuif (France), Foster City (USA), Bucuresti (Romania), Izmir (Turkey), Pasadena (USA), Hong Kong

N°39 Daclatasvir/Sofosbuvir and Ribavirin 800 mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: the cleo experience

A. Pellicelli, V. Messina, P. Tarquini, V. Pace Palitti, F. Ceccherini Silberstein, M. Pompili, R. Gulminetti, G. Cerasari, C. D’Ambrosio, R. Villani, L. Fondacaro, S. Dell’isola , S. Babudieri, V. Iovinella, F. Di Candilo, F. Chiesara, V.C. Di Maio, F.R. Ponziani, R. Sacco, A. Izzi, A. Moretti, V. Giannelli, C.F. Perno, G. Barbarini for the CLEO Group ‐ Rome, Caserta, Teramo, Pescara, Pavia, Viterbo, Sassari, Naples, Perugia, Pisa

N°40 Emerging players in liver fibrosis regression in a chronic murine model of hepatic injury

M. Crescenzi, C. Frasson, D. Gabbia, S. De Martin, M.T. Conconi, G. Basso, P. Burra, F.P. Russo ‐ Padua

N°41 Portosystemic shunts in cirrhosis are associated to more complications and deteriorated quality of life. An international cohort study

M. Simón‐Talero, D. Roccarina, A. Majumdar, E.A. Tsochatzis, J. Martínez, C. Picón, A. Albillos, K. Lampichler, D. Toth, T. Reiberger, A. Baiges, A. Darnell, V. Hernandez‐Gea, G. Low, J. G. Abraldes, P. Tandon, E. Llop, M. Lopez, J.L. Calleja, M. Praktiknjo, G. Kukuk, J. Trebicka, M. Maurer, A. Berzigotti, A. Zipprich, C. Ripoll, M. Triolo, V. La Mura, G. Vangrinsven, W. Laleman, R. Garcia‐Martinez, R. Bañares, A. Dam, A. Krag, S. Augustin, J. Genescà and the Baveno VI‐SPSS group Barcelona (Spain), London (UK), Alcalá (Spain), Madrid (Spain), Vienna (Austria), Edmonton (Canada), Bonn (Germany), Berne (Switzerland), Halle‐Saale (Germany), Milan, Leuven (Belgium), Odense (Denmark)

N°42 High rate of misclassification of fibrosis stage using Transient elastography thresholds to prioritize HCV patients for antiviral treatment

V. Calvaruso, F. Bronte, B. Magro, E. Conte, S. Petta, D. Cabibi, A. Craxì, C. Cammà, V. Di Marco ‐ Palermo




N°43 The prevalence of liver diseases due Hepatitis C Virus (HCV) in Sicily: a population‐based survey

F. Cartabellotta, V. Calvaruso, C. Paci, F. Magliozzo, V. Milazzo, C. Crisafulli, C. Lo Curcio, M. Russello, A. Digiacomo, L. Galvano, L. Spicola, V. Di Marco RESIST‐HCV (Rete Sicilia Selezione Terapia‐HCV), Società Italiana di Medicina Generale (SIMG) Sicilia

N°44 HCC onset and features among chronic hepatits B patients treated with nucleos(t)ide analogues

M. Schranz, M. De Giorgio, G. Conte, L. Pasulo, G. Magini, S. Fagiuoli ‐ Bergamo

N°45 Effect of interferon free antiviral therapy on glomerular and tubular kidney involvement in HCV child‐A cirrhosis

D. Palazzo, E. Biliotti, F. Tinti, A. Bachetoni, L. Volpicelli, A. Cappoli, M.D. D’Alessandro, R. Labriola, P. Perinelli, S. Grieco, M. Subic, I. Umbro, P. Rucci, A.P. Mitterhofer, G. Taliani ‐ Rome, Bologna

N°46 The old patient in DAA era: real life reports on 5925 patients from the LOMBARDY HCV NETWORK

L. Pasulo, A. Aghemo, S. Fargion, A. Spinetti, G. Cologni, F. Maggiolo, G. Rizzardini, M. Puoti, R. Bruno, L. Minoli, M. Zuin, C. Uberti, T. Quirino, A. D'Arminio Monforte, A. Colli, M.G. Rumi, C. Iegri, S. Fagiuoli, M. Colombo ‐ Milan, Brescia, Bergamo, Pavia, Busto Arsizio (VA), Lecco

N°47 Genotype 3 infection in DAA era: reports of a real life NORTHERN ITALY NETWORK FOR VIRAL HEPATITIS after 2 years by the start

L. Pasulo, A. Aghemo, T. Quirino, P. Viganò, P. Bonfanti, E. Buscarini, M. Strazzabosco, M. Puoti, M. Vinci, P. Perini, M. Colpani, M. Colombo, S. Fagiuoli ‐ Bergamo, Milan, Busto Arsizio (VA), Legnano (MI), Lecco, Crema (CR), Monza (MB), Ponte San Pietro (BG)

N°48 Pre‐emptive post‐liver transplant (LT) HCV treatment with DAAS: proof of concept from a pilot study

L. Pasulo, C. Mazzarelli, C. Iegri, L. De Carlis, R. Viganò, F. Donato, G. Rossi, A. Zanetto, S. Shalaby, S. Fagiuoli, L. Belli ‐ Bergamo, Milan, Padua

N°49 Early Changes in non invasive assessment of liver fibrosis in hepatitis C virus‐infected patients treated with DAAs: preliminary reports

C. Iegri, L. Pasulo, M. Colpani, L. Sangiovanni, G. Rizzatti, M. Schranz, G. Magini, M. De Giorgio, M.G. Lucà, G. Gaffuri, S. Fagiuoli ‐ Bergamo

N°50 Treatment of chronic Hepatitis C in Lombardia: an analysis on the safety and efficacy of DAA therapy in 5457 patients

A. Aghemo, L. Pasulo, M. Puoti, S. Zaltron, F. Maggiolo, G. Rizzardini, S. Fargion, R. Bruno, M. Zuin, T. Quirino, M.G. Rumi, A. Pan, P. Grossi, A. Rossini, A. Corbellini, S. Fagiuoli ‐ Milan, Brescia, Bergamo, Pavia, Busto Arsizio (VA), Cremona, Varese, Vizzolo Predabissi (MI)




INFORMAZIONI GENERALI Sede: Aula Magna Università di Roma “Sapienza” P.le A. Moro, 5 00185 ROMA www.uniroma1.it/ateneo/dove‐siamo

Provider E.C.M. (ID 1547): A.I.S.F. ‐ Associazione Italiana per lo Studio del Fegato Via Alfredo Catalani, 39 ‐ 00199 ROMA Tel. e Fax: 06‐86399303 E‐mail: [email protected]

Segreteria Organizzativa: SPAZIO CONGRESSI S.r.l. Via Alfredo Catalani, 39 ‐ 00199 ROMA Tel. e Fax: 06‐86204308 E‐mail: [email protected]

www.webaisf.org

Modalità di partecipazione: Socio A.I.S.F. (in regola con il versamento delle quote associative): partecipazione gratuita Non Socio A.I.S.F.: € 260,00 (inclusa IVA 22%)

e comprende: Partecipazione ai lavori congressuali Kit congressuale Coffee breaks Colazioni di lavoro

Nuovi Soci A.I.S.F. Per accedere in qualità di Socio A.I.S.F. all’Evento Formativo e, pertanto, per usufruire della quota agevolata, è necessario iscriversi all’A.I.S.F. la cui modulistica è presente sul sito: www.webaisf.org o contattare direttamente la Segreteria A.I.S.F. L’iscrizione all’A.I.S.F. dà diritto alla partecipazione gratuita alle Riunioni Istituzionali “Riunione Generale Annuale”, “Riunione Monotematica” e “Special Conference”, all’abbonamento gratuito alla rivista Digestive and Liver Disease, all’utilizzo gratuito dell’App di A.I.S.F. ed a ricevere qualsiasi informazione relativa all’attività dell’Associazione.

Modalità di pagamento (Non Socio A.I.S.F.): tramite bonifico bancario intestato alla Segreteria Organizzativa “SPAZIO CONGRESSI S.r.l.” tratto sulla BANCA INTESA SANPAOLO S.p.A. ‐ Filiale di Roma 03 Montesacro n. 00453 ‐ IBAN: IT 77 Q 03069 03202 100000031635. N.B.: Le iscrizioni prive di compilazione e spedizione della Scheda di Pre‐Iscrizione unitamente alla copia del pagamento non saranno prese in considerazione e, pertanto, considerate nulle. Cancellazione e rimborsi: Le cancellazioni pervenute entro il 08 Febbraio 2017, tramite comunicazione scritta alla Segreteria Organizzativa, daranno diritto ad un rimborso totale dell’importo versato, detratto l’importo di € 15,00 per spese amministrative. Superata la data del 08 Febbraio 2017 non saranno riconosciuti rimborsi. I rimborsi saranno effettuati solo dopo il termine dell’Evento.

E.C.M. ‐ Educazione Continua in Medicina e Destinatari Attività Formativa L’Evento Formativo ID 1547‐178700 è accreditato per n. 350 partecipanti, per le seguenti categorie professionali: Biologo e Medico Chirurgo specializzate per le seguenti discipline: Gastroenterologia; Malattie Infettive; Medicina Interna; Chirurgia Generale; Microbiologia e Virologia; Medicina Generale (Medici Di Famiglia); con N° 2,2 Crediti.

Obiettivo Formativo E.C.M. ‐ Educazione Continua in Medicina: Epidemiologia ‐ Prevenzione e Promozione della Salute con Acquisizione di Nozioni Tecnico‐Professionali.

Procedure di attestazione della partecipazione e valutazione dell’apprendimento ai fini E.C.M. ‐ Educazione Continua in Medicina: Ogni partecipante potrà conseguire i crediti assegnati all’Evento rispettando i seguenti requisiti:

compilazione dell’Autodichiarazione di apprendimento completa di Anagrafica partecipante; partecipazione al 90% dell'intera attività formativa con verifica tramite “badge elettronico” in entrata e in uscita.

Il mancato rispetto dei suindicati requisiti non darà diritto ai crediti E.C.M., ma solamente all’attestato di partecipazione. L’attestato E.C.M. verrà spedito a tutti i partecipanti che ne avranno diritto dopo il termine dell’Evento all’indirizzo di posta elettronica riportato sul questionario.

PROGRAMMA.ANN.MEET.2017.rev.del 13 Gen.2017 · 12.15‐12.30 External validation of the ITA.LI.CA...

Documents

Transcript of PROGRAMMA.ANN.MEET.2017.rev.del 13 Gen.2017 · 12.15‐12.30 External validation of the ITA.LI.CA...